Lymphatic system

BlueSphere Bio to Present at the 25th Annual BIO CEO & Investor Conference

Retrieved on: 
Monday, February 6, 2023
AML, Conference, Acute myeloid leukemia, TCR, ALL, MDS, Patient, BIO, Acute leukemia, Lymphatic system, Pharmaceutical industry

PITTSBURGH, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio , a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced Keir Loiacono, Chief Executive Officer of BlueSphere Bio, will present a corporate overview at the 2023 BIO CEO & Investor Conference held in New York City, NY from February 6-9, 2023.

Key Points: 
  • PITTSBURGH, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio , a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced Keir Loiacono, Chief Executive Officer of BlueSphere Bio, will present a corporate overview at the 2023 BIO CEO & Investor Conference held in New York City, NY from February 6-9, 2023.
  • The in-person presentation will highlight the Company’s first and lead product candidate, BSB-1001, currently being developed for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in conjunction with allogeneic hematopoietic stem cell transplantation (alloSCT).
  • The Company anticipates filing its first investigational new drug application later this year.
  • For more information about the BIO CEO & Investor Conference, please refer to the conference website at www.bio.org/events/bio-ceo-investor-conference .

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Retrieved on: 
Thursday, February 2, 2023
AML, Hematology, Society, Food, Safety, Consultant, New Year, IND, Cancer, Immunoglobulin G, American Society of Hematology, Therapy, IPSC, Commercial, Lymphatic system, NK, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acute myeloid leukemia, GT, Trike, Letter, Fine chemical, Management, Pharmaceutical industry

BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, issued an open letter from the CEO to shareholders, detailing the Company’s recent activities.

Key Points: 
  • BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, issued an open letter from the CEO to shareholders, detailing the Company’s recent activities.
  • The full letter is published below:
    I am proud to say that we have made significant progress towards fulfilling our corporate mission.
  • On the corporate development side our board and executives continue to manage the task of taking GT Biopharma’s promising assets into the clinic.
  • We also want to thank our employees for whom GT Biopharma’s innovations would not be possible without their hard-won efforts.

Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Retrieved on: 
Tuesday, January 31, 2023
Survival, Food, Safety, File, MSB, Inflammation, IND, Mortality, Biomarker, CRL, Endpoint security, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Lymphatic system, First, MESO, SR, Priority review, Pharmaceutical industry, Mesoblast

If remestemcel-L receives FDA approval, it will be the first allogeneic “off-the-shelf” cellular medicine to be approved in the United States, and the first therapy for children under 12 years old with SR-aGVHD.

Key Points: 
  • If remestemcel-L receives FDA approval, it will be the first allogeneic “off-the-shelf” cellular medicine to be approved in the United States, and the first therapy for children under 12 years old with SR-aGVHD.
  • The BLA resubmission will have a review period up to six months from filing upon acceptance by FDA.
  • “There is an urgent need for a therapy that improves the dismal survival outcome in children with SR-aGVHD” said Dr. Silviu Itescu, Chief Executive of Mesoblast.
  • “Our team has worked tirelessly over the past two years to provide a comprehensive response to the FDA.

BlueSphere Bio Appoints Erkut Bahceci, M.D., as Chief Medical Officer

Retrieved on: 
Monday, January 30, 2023
AML, Medicine, National Institutes of Health, Acute leukemia, Astellas Pharma, Lymphatic system, Mercy Hospital, Immunotherapy, Cancer, Marmara University, TCR, ALL, Takeda Pharmaceutical Company, Therapy, Pediatric Hematology and Oncology, CAR, Drug development, MDS, Patient, National Heart, Lung, and Blood Institute, Clinical trial, Dasatinib, Acute myeloid leukemia, Faculty, Oncology, Senior, Internal medicine, Associate, Research, Bayer, Pharmaceutical industry, Hematology, Takeda

PITTSBURGH, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the appointment of Erkut Bahceci, M.D., as Chief Medical Officer.

Key Points: 
  • PITTSBURGH, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the appointment of Erkut Bahceci, M.D., as Chief Medical Officer.
  • Dr. Bahceci added, “This is an incredibly exciting time to join BlueSphere Bio.
  • Despite the effectiveness of allogeneic stem cell transplants for a broad range of hematological malignancies, a significant number of patients relapse.
  • He began his career in the pharmaceutical industry at Bayer, where he served as Associate Director of Medical Sciences-Oncology.

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Retrieved on: 
Friday, January 27, 2023
Rituximab, Food, Lymphoma, Lymphatic system, Lenalidomide, Blood, NHL, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Neoplasm, Investigational New Drug, B-cell lymphoma, Pharmaceutical industry, Vaccine, Salinicola salarius

HOUSTON, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the presentation of preclinical data showing SP-3164’s activity in non-Hodgkin’s lymphoma (NHL) animal models. In a model of diffuse large B-cell lymphoma, SP-3164 exhibited synergistic activity with the approved anti-CD20 drug rituximab, resulting in the complete elimination of tumors in 50% of treated mice. The combination also performed significantly better than the approved regimen, lenalidomide and rituximab. These data were presented by Aundrietta Duncan, Ph.D., Salarius’ director of non-clinical development, at the inaugural Molecular Glue Drug Development Summit.

Key Points: 
  • In a model of diffuse large B-cell lymphoma, SP-3164 exhibited synergistic activity with the approved anti-CD20 drug rituximab, resulting in the complete elimination of tumors in 50% of treated mice.
  • The combination also performed significantly better than the approved regimen, lenalidomide and rituximab.
  • These data were presented by Aundrietta Duncan, Ph.D., Salarius’ director of non-clinical development, at the inaugural Molecular Glue Drug Development Summit.
  • Dr. Duncan’s presentation is available for viewing in the Investors Events and Presentations section of Salarius’ website here .

Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer

Retrieved on: 
Thursday, January 26, 2023
Cell, Master of Science, Yale New Haven Hospital, Tisagenlecleucel, MBA, University of Pennsylvania, Oncology, Hematology, Icahn, Assistant, Immunity, MD, Tumor microenvironment, Immunotherapy, Memorial Sloan Kettering Cancer Center, Cancer, B cell, DC, Harvard Medical School, Bhardwaj, University, Patient, NK, Advanced Cell Therapeutics, Peter Gray (bioengineer), Lymphatic system, Macrophage, DMD, Icahn School of Medicine at Mount Sinai, Research, Doctor of Philosophy, Vaccine, Novartis

Under the agreement, Cell BioEngines will utilize Icahn Mount Sinai’s technology platform to develop discrete immune cell-based therapies, such as subtypes of dendritic cells (DC), NK cells, and macrophages, previously inaccessible to cancer patients.

Key Points: 
  • Under the agreement, Cell BioEngines will utilize Icahn Mount Sinai’s technology platform to develop discrete immune cell-based therapies, such as subtypes of dendritic cells (DC), NK cells, and macrophages, previously inaccessible to cancer patients.
  • Under the terms of the agreement, Icahn Mount Sinai will be eligible to receive an undisclosed upfront cash payment as well as additional milestones based on development, regulatory, and commercial milestones.
  • The primary product focus of Cell BioEngines is to stimulate patients' adaptive immune system using a DC-based therapeutic cancer vaccine, now well-known for driving response in treatment-naïve and immunotherapy patients.
  • “Our immune cell generation platform can generate billions of functional dendritic cell subtypes and provide an option for developing off-the shelf cellular vaccine for cancer immunotherapy,” said Dr. Balan, who invented the technology with Dr. Bhardwaj.

Atossa Therapeutics Issues Letter to Shareholders

Retrieved on: 
Wednesday, January 25, 2023
Exemestane, Breast cancer, Food, Safety, Patient, Lymphatic system, COVID-19, Cancer, Radiation-induced lung injury, SERM, Vaccine, Risk, Survival, Goserelin, Breast, DCT, Letter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Incidence, Patent, Lung cancer, Health, ER, Growth, Neoplasm, Woman, 1836 U.S. Patent Office fire, Pharmacotherapy, Axis, Degenerative disease, Therapy, MBD, Pharmaceutical industry, Medical imaging, Atossa

SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces the issuance of the following Letter to Shareholders from Steven C. Quay, M.D., Ph.D., the Company’s CEO and Chairman:

Key Points: 
  • SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces the issuance of the following Letter to Shareholders from Steven C. Quay, M.D., Ph.D., the Company’s CEO and Chairman:
    2022 was a year of significant progress for Atossa.
  • We currently have Phase 2 studies ongoing in the prevention and treatment settings, both focused on areas of unmet medical need.
  • Our investment, which totaled $4.7 million and resulted in Atossa owning approximately 19% of the outstanding capital stock of DCT, closed in December 2022.
  • On behalf of the board of directors, management, and employees of Atossa Therapeutics, we thank you for your investment and continued support of our Company.

Bionano Laboratories Expands its Clinical Testing Menu with Launch of its First OGM-Based Laboratory Developed Test (LDT) for Hematological Malignancies

Retrieved on: 
Tuesday, January 24, 2023
AML, Disease, Malignancy, Diagnosis, OGM, ALL, Blood, Biomarker, SVS, Myelodysplastic syndrome, Bone marrow, B-cell lymphoma, Chronic lymphocytic leukemia, CLL, Genome, Facioscapulohumeral muscular dystrophy, Lymphatic system, MDS, Patient, SAN, CML, FSHD, Workflow, LDT, Acute lymphoblastic leukemia, Acute myeloid leukemia, Pharmaceutical industry

OGM-Dx HemeOne is the second OGM-based LDT launched by Bionano Laboratories, following the laboratory’s LDT for facioscapulohumeral muscular dystrophy (FSHD), which was released in September 2022.

Key Points: 
  • OGM-Dx HemeOne is the second OGM-based LDT launched by Bionano Laboratories, following the laboratory’s LDT for facioscapulohumeral muscular dystrophy (FSHD), which was released in September 2022.
  • “We are pleased to see the launch of Bionano Laboratories' LDT for heme malignancies, which can assist patients in their diagnostic and prognostic journey.
  • Our laboratory’s robust LDT validation is designed to provide a comprehensive evaluation of genome wide SVs that will allow oncologists to assess the best potential therapies for their malignancy patients.
  • We believe the continued development of OGM-based LDTs will allow Bionano Laboratories to help create a roadmap for how OGM might be leveraged in a clinical setting,” stated Justin Leighton, vice president of laboratory business at Bionano Laboratories.

Globally-Acclaimed Wellness Leader Introduces THE WELL at Chileno Bay, Auberge Resorts Collection

Retrieved on: 
Wednesday, January 18, 2023
Master, Drink, Moon, Ageing, Temperature, The Third Mind Movements, Arrival, Relaxation, LOS, Sleep, MD, Antioxidant, Yoga, Health, Motion, Calendar, Partnership, WELL, Nervous system, Water, Lymphatic system, Meditation, Science, Flower, Movement, Nature, Taste, Sea, Alternative, Interior, Bath House, Warwickshire, Tourism, Hotel, Hospital, Nightclub

LOS CABOS, Mexico , Jan. 18, 2023  /PRNewswire-PRWeb/ -- THE WELL, your one-stop shop for wellness, and Chileno Bay Resort & Residences, Auberge Resorts Collection, the award-winning contemporary, oceanfront resort in Los Cabos, announce the highly anticipated opening of THE WELL at Chileno Bay on January 18, 2023 on the shores of the Sea of Cortés. With the announcement of the first West Coast and second international location for THE WELL, the leading wellness brand continues to increase its global footprint through its partnership with renowned hotel group Auberge Resorts Collection. THE WELL brings its personalized approach to care to yet another one of the world's most desirable destinations — addressing the physical, mental and spiritual aspects of well-being to help guests feel their best, well beyond their stay.

Key Points: 
  • With the announcement of the first West Coast and second international location for THE WELL, the leading wellness brand continues to increase its global footprint through its partnership with renowned hotel group Auberge Resorts Collection .
  • "For many, Chileno Bay represents a free-spirited playground that's perfectly balanced by the calming nature of the wild elements around us."
  • said Roger Ponce, regional vice president and general manager, Chileno Bay Resort & Residences, Auberge Resorts Collection.
  • The wellness rooms and suite also feature an Eight Sleep Pod 3 Cover to enhance guests' sleep and recovery.

TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology

Retrieved on: 
Tuesday, January 17, 2023
Cell, TC, PLC, Lymphatic system, Immunotherapy, Monroe Dunaway Anderson, MD, Patient, MD Anderson Cancer Center, Holding, University, Behavior, Anderson, Medical imaging, Immunology

EDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announces a strategic collaboration with The University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.

Key Points: 
  • EDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announces a strategic collaboration with The University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.
  • The collaboration brings together MD Anderson's clinical trial infrastructure and the translational research expertise of its immunotherapy platform with the clinical data of TC BioPharm's targeted gamma-delta T cell oncology pipeline.
  • "We are enthusiastic about working with MD Anderson to further our knowledge of gamma delta T cells in order to help TC Biopharm develop future trials and treatments using our platform therapy OmnImmune," said Bryan Kobel, CEO of TC BioPharm.
  • "This collaboration reinforces our mutual commitment to accelerating the discovery and development of cell therapies, and it highlights TC Biopharm's expertise in the gamma delta T cell space."